Effect of Astragaloside Ⅳ on HBV Expression in Human Peripheral Blood Mononuclear Cell
Objective:To explore the effect of astragaloside Ⅳ on the expression of HBV in peripheral blood mononuclear cell(PBMC)of patients with post-hepatitis B cirrhosis.Methods:Twenty patients with post-hepatitis B cirrhosis who were treated in jiangxi provincial people's hospital from February 2019 to February 2022 were selected.PBMCs were isolated and cultured,and then divided into control group,lamivudine group and astragaloside Ⅳ group according to the type of drugs contained in the culture medium.The lamivudine group and astragaloside Ⅳ group were further divided into three subgroups with low,medium and high concentration according to the final concentration of the drug.After culturing for 1 week,the expressions of HBsAg,HBeAg,HBV-DNA and HBV-cccDNA were detected in each group.Results:Compared with the control group,the expression of HBsAg in each concentration group of astragaloside Ⅳ was significantly decreased,and the difference was statistically significant(P<0.05),while the expression of HBeAg in each concentration group of astragaloside Ⅳ had no statistical difference(P>0.05).There was no significant difference in the expression of HBV-DNA in the low concentration group of astragaloside Ⅳ(P>0.05).The expression of HBV-DNA in the middle and high concentration groups of astragaloside Ⅳ decreased significantly,and the difference was statistically significant(P<0.05).There was no significant difference in the expression of HBV-cccDNA in each concentration group of astragaloside Ⅳ(P>0.05).Compared with the control group,the expressions of HBsAg,HBeAg,and HBV-DNA in each concentration group of lamivudine were significantly decreased,and the difference was statistically significant(P<0.05).There was no significant difference in the expression of HBV-cccDNA in the lamivudine low concentration group(P>0.05).The expression of HBV-cccDNA in the middle and high concentration groups of lamivudine was significantly decreased,and the difference was statistically significant(P<0.05).Spearman test analysis indicated that the concentration of astragaloside Ⅳ was linearly and negatively correlated with the expression levels of HBsAg,HBeAg,HBV-DNA,and HBV-cccDNA,and the negative correlation with HBsAg and HBV-DNA was statistically significant(P<0.05).Conclusion:Astragaloside Ⅳ can inhibit HBV replication in PBMC of patients with post-hepatitis B cirrhosis to a certain extent,which can provide a new therapeutic idea to address HBV relapse after liver transplant.
Astragaloside IVHepatitis B VirusPost-hepatitis B CirrhosisPeripheral Blood Mononuclear Cells
NETL
NSTL
万方数据
